SCHEMBL361400

SCHEMBL361400

O=CNC1CCOCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772329 0.85
SCHEMBL18924672 0.85
SCHEMBL18924687 0.85
SCHEMBL19658308 0.80 ADH1B (1.00)
SCHEMBL115609 0.80
SCHEMBL21997344 0.80 ADH1B (1.00)
SCHEMBL21757725 0.80 ADH1B (0.52)
Hydrochloric Acid SCHEMBL9205102 0.77
Hydrochloric Acid SCHEMBL4095046 0.77
SCHEMBL29173157 0.75 ADH1B (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12006320-B2 Heterocyclic derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2024-06-11 US claimed
CN-113999197-A Preparation method of 4-aminomethyl tetrahydropyran 苏州艾缇克药物化学有限公司 2022-02-01 CN claimed
US-20210395258-A1 HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2021-12-23 US claimed
US-11078204-B2 Heterocyclic derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2021-08-03 US claimed
WO-2020102198-A1 HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2020-05-22 WO claimed
US-20200148689-A1 HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2020-05-14 US claimed
EP-2450374-B9 PEPTIDE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-11-23 EP claimed
US-9394297-B2 Amides as pim inhibitors AMGEN INC. (US) 2016-07-19 US claimed
US-9260500-B2 Peptide and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-16 US claimed
US-20150329538-A1 AMIDES AS PIM INHIBITORS AMGEN INC. (US) 2015-11-19 US claimed
JP-2011529054-A 2011-12-01 JP claimed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US claimed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP claimed
WO-2010035032-A1 CALCIUM ION CHANNEL MODULATORS &amp; USES THEREOF LECTUS THERAPEUTICS LIMITED (GB) 2010-04-01 WO claimed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO claimed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US claimed
WO-2009133387-A1 INDOLE- 3 -GLYOXYLAMIDE DERIVATIVES FOR USE AS CALCIUM ION CHANNEL MODULATORS LECTUS THERAPEUTICS LIMITED (GB) 2009-11-05 WO claimed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 US claimed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 EP claimed
US-5977102-A INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; DR. KARL THOMAE GMBH (DE) 1999-11-02 US claimed